Article focus {#section5-2046-3758.69.BJR-2017-0149.R2}
=============

-   The duration of application of a tourniquet is related to the incidence of deep vein thrombosis (DVT) following total knee arthroplasty (TKA).

-   We examined the effect of releasing the tourniquet immediately after introducing the components on the incidence of DVT in a series of TKAs.

Key messages {#section6-2046-3758.69.BJR-2017-0149.R2}
============

-   There was a reduced incidence of DVT in patients in whom the tourniquet was released early.

-   Other clinical outcomes were non inferior with this earlier tourniquet release strategy.

Strengths and limitations {#section7-2046-3758.69.BJR-2017-0149.R2}
=========================

-   Strengths: This was a comparative cohort study, the associated surgical and clinical factors were controlled effectively, and this is the first study to investigate the relationship between the timing of release of the tourniquet and the incidence of DVT following TKA.

-   Limitations: None of the patients received chemoprophylaxis for DVT; there was no long-term follow-up and some patients may have developed a DVT after the time of final assessment, three months post-operatively.

Introduction {#section8-2046-3758.69.BJR-2017-0149.R2}
============

Total knee arthroplasty (TKA) is a successful, safe, and cost-effective procedure for reducing pain and restoring function in patients with severe osteoarthritis and rheumatoid arthritis affecting the knee.^[@bibr1-2046-3758.69.BJR-2017-0149.R2],[@bibr2-2046-3758.69.BJR-2017-0149.R2]^ Venous thromboembolism (VTE), including both deep vein thrombosis (DVT) and pulmonary embolism (PE), is associated with significant post-operative morbidity and mortality.^[@bibr3-2046-3758.69.BJR-2017-0149.R2]^ Although a DVT can occur throughout a deep vein, thrombi usually form distally within the deep veins of the lower limb. A thrombus can extend proximally or break off and travel to the lungs, causing a PE.^[@bibr4-2046-3758.69.BJR-2017-0149.R2]^ The rate of DVT following TKA is high and DVT is associated with a large clinical and economic burden.^[@bibr5-2046-3758.69.BJR-2017-0149.R2]-[@bibr7-2046-3758.69.BJR-2017-0149.R2]^

A tourniquet is commonly used during TKA as it improves visualisation, shortens the operating time and decreases intra-operative bleeding, thus ensuring better cementation.^[@bibr8-2046-3758.69.BJR-2017-0149.R2]-[@bibr11-2046-3758.69.BJR-2017-0149.R2]^ However, the complications of using a tourniquet include wound dehiscence, swelling of the leg, oozing, infection, and DVT.^[@bibr12-2046-3758.69.BJR-2017-0149.R2]-[@bibr14-2046-3758.69.BJR-2017-0149.R2]^ Although highly debated for many years, tourniquets remain widely used in orthopaedic surgery. Recent studies have focused on how to further optimise their use in TKA.^[@bibr15-2046-3758.69.BJR-2017-0149.R2]-[@bibr18-2046-3758.69.BJR-2017-0149.R2]^ An increased length of tourniquet time may increase the risk of DVT due to increased venous stasis and potential damage to calcified vessels inducing an inflammatory stimulus.^[@bibr19-2046-3758.69.BJR-2017-0149.R2]^ We undertook a study to detect the effect of the release of the tourniquet immediately after implantation of the components on the incidence of DVT after primary TKA. The hypothesis was that patients treated with release of the tourniquet at this time would have a reduced incidence of DVT compared with those in whom the tourniquet was released after applying the dressings.

Patients and Methods {#section9-2046-3758.69.BJR-2017-0149.R2}
====================

This study was a combined prospective and retrospective cohort study. Patients with osteoarthritis or rheumatoid arthritis who underwent unilateral primary TKA between November 2015 and November 2016 were considered for enrollment. Exclusion criteria included pre-operative signs of coagulopathy, such as abnormal coagulation test values or continuing anticoagulant treatment, poorly controlled diabetes mellitus or hypertension and a history of previous surgery to the knee.

All patients underwent TKA under the same laryngeal mask anaesthestic protocol. The lower limb was elevated to allow pooled blood to drain, after which the tourniquet was inflated to 250 mmHg. A standard procedure involving a posterior cruciate-substituting cemented prosthesis (Genesis II Oxinium; Smith & Nephew, Memphis, Tennessee) was performed by a senior surgeon(GL) using a longitudinal midline incision and a medial parapatellar approach. Peripheral femoral and tibial osteophytes were removed and intramedullary and extramedullary guides were used for preparation of the femur and tibia, respectively. After introduction of the components, the tourniquet was released and the wound was closed following irrigation and the injection of a single dose of morphine, bupivacaine and betamethasone, diluted by 60 ml of sterile normal saline into the soft tissues around the knee.^[@bibr20-2046-3758.69.BJR-2017-0149.R2]^ One drainage tube was used. This group of patients was compared with a retrospective cohort of 200 identical unilateral procedures undertaken by the same surgeon between March 2014 and October 2015, in which the tourniquet was not released until after the dressings were applied. Data for this group were obtained from the medical records using the same exclusion criteria as for the study group.

All patients received post-operative oral non-steroidal anti-inflammatory medication with celecoxib capsules(Pfizer, New York City, New York), 200 mg, once daily, except for those with contra-indications. None received chemical thromboprophylaxis. All were mobilised, using a routine physiotherapy protocol, on the first post-operative day after removal of the drainage tube. The criteria for blood transfusion were a serum level of haemoglobin of \< 8 g/dL or symptomatic anaemia at a level of \< 10 g/dL. All patients underwent ultrasonography with ultrasound (Philips iU22, Amsterdam, The Netherlands) of both lower limbs by physicians who were blinded to the tourniquet strategy that had been used, between five and seven days post-operatively. A thrombus located above the knee including one in the iliac, femoral, superficial or deep saphenous and popliteal vein was defined as a proximal DVT. One located below the knee, in the anterior or posterior tibial, peroneal, soleal vein or small tertiary vessels was defined as a distal DVT. A multi-vein thrombus was assigned as proximal or distal based upon the larger vein that was involved.

Various baseline demographic characteristics and intra- and post-operative data were extracted for analysis. All patients were reviewed at least three months post-operatively. Those who had developed a DVT during their admission underwent further ultrasonography of both lower limbs one and three months post-operatively. The blood loss, including the volume of intra-operative suction and post-operative drainage and the requirement for transfusion, were recorded. The blood loss was calculated as described by Gross,^[@bibr21-2046-3758.69.BJR-2017-0149.R2]^ using the difference between the level of haemoglobin or haematocrit pre-operatively and on the first post-operative day (15 to 24 hours), accounting for the height and weight of the patient and using a correction factor for gender. The bleeding-related outcomes, and the tourniquet time and operating time, were considered as secondary outcomes.

The study had ethical approval and all patients gave informed consent.

Statistical analysis {#section10-2046-3758.69.BJR-2017-0149.R2}
--------------------

Data analysis was performed using standard statistical software (SPSS, version 22.0, 2013, IBM Corp, Armonk, New York). Categorical variables were presented as absolute numbers and relative frequencies, of which the chi-squared test was used to test the differences as shown using odds ratios (OR) and corresponding 95% Confidence Intervals (CIs). Continuous variables were presented as the mean and standard deviation ([sd)]{.smallcaps}. The Student's *t*-test was used to investigate parametric data, these data are presented with mean difference and 95% CI. Results were considered significant with p-values \< 0.05.

Results {#section11-2046-3758.69.BJR-2017-0149.R2}
=======

A total of 472 patients with primary unilateral TKAs in the combined prospective and retrospective cohorts were identified. A total of 72 patients, 44 in the early release group and 28 patients in the late release group, were excluded. An intended total of 400 patients were recruited for this trial. The date of the final follow-up was 16 February 2017. Four patients in the prospective cohort who were lost to follow-up were excluded, leaving 196 in the prospective early release group and 200 in the retrospective late release group for the final analysis. A flow-diagram is shown in [Figure 1](#fig1-2046-3758.69.BJR-2017-0149.R2){ref-type="fig"}. The groups were matched based on the following pre-operative characteristics: age, side of TKA, gender, BMI, diagnosis, and pre-operative level of haemoglobin ([Table I](#table1-2046-3758.69.BJR-2017-0149.R2){ref-type="table"}).

![Patients' flow diagram (TKA, total knee arthroplasty).](bonejointres-06-535-g001){#fig1-2046-3758.69.BJR-2017-0149.R2}

###### 

The demographics of the patients

  Parameters                            Early release group (n = 196) (mean, [sd]{.smallcaps})   Late release group (n = 200) (mean, [sd]{.smallcaps})   Mean difference (95% CI)   p-value
  ------------------------------------- -------------------------------------------------------- ------------------------------------------------------- -------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------
  Age (yrs)                             69.4 (7.2)                                               68.6 (8.1)                                              0.8 (-3.77 to 5.34)        0.674^[\*](#table-fn1-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^
  Left/right (n)                        102, 94                                                  113, 87                                                 N/A                        0.373^[†](#table-fn2-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^
  Male/female (n)                       84, 112                                                  79, 121                                                 N/A                        0.497^[†](#table-fn2-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^
  BMI (kg/m^2^)                         25.7 (2.2)                                               26.1 (1.9)                                              -0.4 (-1.80 to 1.06)       0.451^[\*](#table-fn1-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^
  Diagnosis (OA or RA)                  189, 7                                                   191, 9                                                  N/A                        0.639^[†](#table-fn2-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^
  Haemoglobin level (g/L)               131.2 (11.3)                                             129.7 (12.7)                                            1.5 (-4.46 to 7.46)        0.682^[\*](#table-fn1-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^
  Tourniquet time (mins)                47.6 (7.8)                                               71.2 (10.8)                                             -23.6 (-25.55 to -21.72)   \< 0.001^[\*](#table-fn1-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}[‡](#table-fn3-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^
  Operating time (mins)                 73.3 (11.4)                                              71.2 (10.8)                                             2.1 (-1.05 to 5.24)        0.152^[\*](#table-fn1-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^
  Intra-operative blood loss (ml)       177.4 (37.2)                                             117.6 (39.4)                                            59.8 (52.33 to 67.42)      \< 0.001^[\*](#table-fn1-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}[‡](#table-fn3-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^
  Post-operative drainage volume (ml)   301.2 (44.7)                                             296.4 (39.5)                                            4.8 (-8.34 to 17.94)       0.466^[\*](#table-fn1-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^
  Calculated blood loss (ml)            907.4 (237.5)                                            894.9 (188.2)                                           12.5 (-10.73 to 35.73)     0.232^[\*](#table-fn1-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^
  Blood transfusion (patients)          9                                                        11                                                      N/A                        0.680^[†](#table-fn2-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^

Student's *t*-test

chi-squared test

Statistically significant

BMI, body mass index; OA, osteoarthritis; RA, rheumatoid arthritis; Hb, haemoglobin; CI, confidence interval; N/A, not applicable

The mean tourniquet time was significantly shorter in the early release group (47.6 minutes, [sd 7.8]{.smallcaps}) than in the late release group (71.2 minutes, [sd]{.smallcaps} 10.8; mean difference = -23.6, 95% CI -25.55 to -21.72, p \< 0.001). The mean operating time in the two groups was not significantly different: early release group (73.3 minutes, [sd]{.smallcaps} 11.4); late release group (71.2 minutes, [sd]{.smallcaps} 10.8; mean difference = 2.1, 95% CI -1.05 to 5.24, p = 0.152). The mean intra-operative blood loss was significantly greater in the early release group (177.4 ml, [sd]{.smallcaps} 37.2) compared with the late release group (117.6 ml, [sd]{.smallcaps} 39.4; mean difference = 59.8, 95% CI 52.33 to 67.42, p \< 0.001). The mean volume of post-operative drainage, total blood loss and transfusion requirement in the two groups were not significantly different ([Table I](#table1-2046-3758.69.BJR-2017-0149.R2){ref-type="table"}).

Two patients in the late release group developed a symptomatic proximal DVT with progressive swelling of the operated limb on the third and fourth post-operative day, respectively. These were identified at the time of the ultrasonography. The total incidence of proximal post-operative DVT was 0.5% (n = 1) in the early release group and 4% (n = 8) in the late release group; this difference was significant (odds ratio (OR) 0.12, 95% CI 0.02 to 0.99, p = 0.02). The incidence of distal DVT was 4.1% (n = 8) in the early release group and 8% (n = 16) in the late release group; this difference was not significant (OR 0.49, 95% CI 0.21 to 1.17, p = 0.102). The total number of patients with a DVT was significantly higher in the late release group (12%, n = 24) than in the early release group (4.6%, n = 9; OR 0.35, 95% CI 0.16 to 0.78, p = 0.008).

Patients with a proximal DVT were treated with rivaroxaban (15mg twice a day for 21 days and then 20 mg daily). Those with a distal DVT were not treated with anticoagulants on the advice of a haematologist. All patients with a DVT underwent further ultrasonography at the time of the review, one and three months post-operatively. Rivaroxaban treatment continued for one month if the thrombus had resolved on ultrasound at that time. Treatment continued for three months in total if it had not. The thrombus had resolved one month post-operatively in one patient in the early release group and three in the late release group with a proximal DVT. Three patients with an asymptomatic proximal DVT in the late release group and two patients in this group with a symptomatic proximal DVT had complete resolution of the thrombus three months post-operatively. The thrombus had resolved completely in all patients with a distal DVT, three months post-operatively. The thrombus did not propagate further in any patient and no patient had a fatal PE. Detailed data is shown in [Table II](#table2-2046-3758.69.BJR-2017-0149.R2){ref-type="table"} and [Table III](#table3-2046-3758.69.BJR-2017-0149.R2){ref-type="table"}.

###### 

Details of patients who had a deep vein thrombosis (DVT)

  Patient (n)                                                                                                                                 Group   Gender   Age (yrs)   BMI    Tourniquet time (mins)   Operation time (mins)   Thrombus location                              Treatment
  ------------------------------------------------------------------------------------------------------------------------------------------- ------- -------- ----------- ------ ------------------------ ----------------------- ---------------------------------------------- -------------
  1                                                                                                                                           ERG     Female   73          26.5   57                       79                      Right posterior tibial and peroneal veins      None
  2                                                                                                                                           ERG     Male     75          27.4   48                       73                      Left posterior tibial vein                     None
  3                                                                                                                                           ERG     Female   68          24.8   51                       71                      Right soleal vein                              None
  4^[†](#table-fn6-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^                                                                       ERG     Female   76          25.1   56                       74                      Right femoral vein                             Rivaroxaban
  5                                                                                                                                           ERG     Male     67          27.1   53                       81                      Left peroneal vein                             None
  6                                                                                                                                           ERG     Female   78          23.7   55                       77                      Left posterior tibial and peroneal veins       None
  7                                                                                                                                           ERG     Female   81          25.6   52                       75                      Left posterior tibial vein                     None
  8                                                                                                                                           ERG     Female   77          27.4   53                       78                      Right peroneal and soleal veins                None
  9                                                                                                                                           ERG     Male     83          26.9   49                       73                      Left posterior tibial vein                     None
  10                                                                                                                                          LRG     Female   76          27.1   71                       71                      Left peroneal vein                             None
  11^[†](#table-fn6-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^                                                                      LRG     Female   68          28.4   69                       69                      Left popliteal vein                            Rivaroxaban
  12                                                                                                                                          LRG     Female   64          24.7   75                       75                      Right posterior tibial vein                    None
  13^[\*](#table-fn5-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}[†](#table-fn6-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^   LRG     Male     59          26.3   73                       73                      Left femoral vein and peroneal vein            Rivaroxaban
  14                                                                                                                                          LRG     Male     66          26.1   81                       81                      Right anterior tibial vein                     None
  15                                                                                                                                          LRG     Female   75          24.8   68                       68                      Left peroneal veins                            None
  16^[†](#table-fn6-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^                                                                      LRG     Female   71          25.3   67                       67                      Left great saphenous vein                      Rivaroxaban
  17                                                                                                                                          LRG     Male     84          27.8   74                       74                      Right peroneal vein and soleal veins           None
  18                                                                                                                                          LRG     Female   81          26.2   71                       71                      Left peroneal vein and small vessels           None
  19                                                                                                                                          LRG     Male     69          28.1   84                       84                      Right femoral vein                             None
  20^[†](#table-fn6-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^                                                                      LRG     Female   73          26.3   77                       77                      Left popliteal vein and small vessels          Rivaroxaban
  21                                                                                                                                          LRG     Female   78          24.7   72                       72                      Right posterior tibial vein                    None
  22                                                                                                                                          LRG     Female   67          23.9   69                       69                      Right peroneal vein                            None
  23^[†](#table-fn6-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^                                                                      LRG     Male     77          26.6   75                       75                      Left femoral and posterior tibial veins        Rivaroxaban
  24^[†](#table-fn6-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^                                                                      LRG     Female   73          28.8   83                       83                      Left femoral vein                              Rivaroxaban
  25                                                                                                                                          LRG     Male     68          22.9   74                       74                      Right posterior tibial and peroneal veins      None
  26                                                                                                                                          LRG     Male     81          27.3   71                       71                      Left peroneal vein                             None
  27^[\*](#table-fn5-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}[†](#table-fn6-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^   LRG     Female   83          28.3   66                       66                      Right femoral and popliteal veins              Rivaroxaban
  28                                                                                                                                          LRG     Female   69          26.2   84                       84                      Right posterior tibial vein                    None
  29                                                                                                                                          LRG     Male     75          25.9   71                       71                      Left posterior tibial vein and small vessels   None
  30^[†](#table-fn6-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^                                                                      LRG     Male     71          24.7   69                       69                      Left femoral vein and small vessels            Rivaroxaban
  31^[†](#table-fn6-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^                                                                      LRG     Female   69          25.7   88                       88                      Left popliteal vein                            Rivaroxaban
  32                                                                                                                                          LRG     Female   77          26.8   81                       81                      Right peroneal vein                            None
  33                                                                                                                                          LRG     Female   79          25.9   73                       73                      Right posterior tibial and peroneal veins      None

proximal DVT

symptomatic DVT

ERG, early release group; LRG, late release group; BMI, body mass index

###### 

Summary of the complications

  Parameters                                                                                     Early release group (n = 196)   Late release group (n = 200)   OR (95% CI)            p-value
  ---------------------------------------------------------------------------------------------- ------------------------------- ------------------------------ ---------------------- ----------------------------------------------------------------------------
  Total DVT^[†](#table-fn9-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^ (n)              9                               24                             0.35 (0.16 to 0.78)    0.008^[\*](#table-fn8-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^
  Proximal DVT (n)                                                                               1                               8                              0.12 (0.02 to 0.99)    0.020^[\*](#table-fn8-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^
  Distal DVT (n)                                                                                 8                               16                             0.49 (0.21 to 1.17)    0.102
  Total complications^[‡](#table-fn10-2046-3758.69.BJR-2017-0149.R2){ref-type="table-fn"}^ (n)   13                              18                             0.72 (0.34 to 1.51)    0.381
  Symptomatic DVT (n)                                                                            0                               2                              0.20 (0.01 to 4.24)    0.160
  Wound drainage (n)                                                                             6                               3                              2.07 (0.51 to 8.41)    0.297
  Skin tension blister (n)                                                                       3                               8                              0.37 (0.10 to 1.43)    0.135
  Marginal necrosis (n)                                                                          1                               2                              0.51 (0.05 to 5.64)    0.574
  Superficial infection (n)                                                                      2                               3                              0.68 (0.11 to 4.10)    0.669
  Deep infection (n)                                                                             1                               0                              3.08 (0.12 to 75.99)   0.312

Statistically significant difference

Number of patients with proximal and distal DVT

Number of patients with symptomatic DVT plus those with other complications

OR, odds ratio; CI, confidence interval; DVT, deep vein thrombosis

p-values calculated using chi-squired test

Excluding those with an asymptomatic DVT, 13 patients (6.6%) in the early release group had a complication of surgery. Six had wound drainage beyond one post-operative week, three had blistering of the skin, one had skin necrosis, two had a superficial infection and one had a deep infection. In comparison, 18 patients (9.0%) in the late release group a complication. Three had wound drainage beyond one post-operative week, eight had blistering of the skin, two had skin necrosis, three had a superficial infection and two had symptomatic DVTs The difference in the rate of complications between the two groups was not significant (OR 0.72, 95% CI 0.34 to 1.51, p = 0.381).

Discussion {#section12-2046-3758.69.BJR-2017-0149.R2}
==========

To our knowledge, this is the first study that assesses the effect of the timing of release of the tourniquet on the incidence of DVT following TKA. We found that early release was associated with a significantly reduced incidence of DVT, without a significant increase in the rate of other complications.

Most surgeons prefer to use a tourniquet during TKA, although the prevalence of peri-operative complications associated with its use has caused much controversy. Abdel-Salam et al^[@bibr22-2046-3758.69.BJR-2017-0149.R2]^ reported an increased incidence of DVT as confirmed by venography, with the use of a tourniquet in TKA. Mori et al^[@bibr23-2046-3758.69.BJR-2017-0149.R2]^ found that the use of a tourniquet was associated with a significantly increased risk of distal DVT, as identified by ultrasound. Many authors have suggested that shortening the tourniquet time will reduce the disadvantages of its use, while preserving the advantages. In a retrospective study by Razak et al,^[@bibr24-2046-3758.69.BJR-2017-0149.R2]^ the incidence of a symptomatic DVT in patients was significantly related to a longer tourniquet time. One patient developed a PE with a tourniquet time of 160 minutes, which was significantly longer than the mean tourniquet time for the whole series. Chung et al,^[@bibr25-2046-3758.69.BJR-2017-0149.R2]^ also reported that the rate of DVT appeared to be increased with a longer tourniquet time, probably due to a longer period of venous stasis and damage to calcified vessels. We have previously undertaken a meta-analysis on the early release of the tourniquet before wound closure and found a tendency to a decreased incidence of DVT with early release.^[@bibr19-2046-3758.69.BJR-2017-0149.R2]^ With the current study, using relatively large prospective and retrospective cohorts, we found a significantly decreased incidence of DVT, identified by ultrasound, with early release of the tourniquet. Most DVTs were asymptomatic. There is evidence, however, that an asymptomatic post-operative DVT is associated with an increased risk of the late development of the post-thrombotic syndrome.^[@bibr26-2046-3758.69.BJR-2017-0149.R2],[@bibr27-2046-3758.69.BJR-2017-0149.R2]^ Thus patients with an asymptomatic DVT should be monitored carefully, although they may not require chemical thromboprophylaxis. We also speculate that an increased rate of asymptomatic DVT may be related to the rate of symptomatic VTE following TKA.^[@bibr23-2046-3758.69.BJR-2017-0149.R2],[@bibr26-2046-3758.69.BJR-2017-0149.R2],[@bibr27-2046-3758.69.BJR-2017-0149.R2]^

Patients undergoing TKA are at a high risk of VTE. Guidelines from many national orthopaedic societies recommend the use of pharmacologic agents and/or mechanical compressive devices for the prevention of VTE in these patients.^[@bibr28-2046-3758.69.BJR-2017-0149.R2],[@bibr29-2046-3758.69.BJR-2017-0149.R2]^ A lower incidence of VTE in Asian patients compared with Western patients undergoing TKA has also been reported,^[@bibr30-2046-3758.69.BJR-2017-0149.R2],[@bibr31-2046-3758.69.BJR-2017-0149.R2]^ and many Asian centres do not routinely use thromboprophylaxis in TKA. A study from Singapore found that both the prevalence and incidence of symptomatic VTE in TKA in patients not receiving thromboprophylaxis was \< 1%.^[@bibr24-2046-3758.69.BJR-2017-0149.R2],[@bibr32-2046-3758.69.BJR-2017-0149.R2],[@bibr33-2046-3758.69.BJR-2017-0149.R2]^ Routine anticoagulation has risks. Sutherland et al^[@bibr34-2046-3758.69.BJR-2017-0149.R2]^ reported an incidence of 4% systemic complications and 12% of wound complications with the use of warfarin, and Chin et al^[@bibr35-2046-3758.69.BJR-2017-0149.R2]^ reported an incidence of bleeding complications of 11% with enoxaparin. Several other studies have also shown that the aggressive use of chemical prophylaxis is accompanied by complications such as delayed wound healing, haematoma and infection. These complications may interfere with rehabilitation, prolong hospitalisation and require further surgery leading to an enhanced burden on society.^[@bibr36-2046-3758.69.BJR-2017-0149.R2]-[@bibr39-2046-3758.69.BJR-2017-0149.R2]^ We do not use routine thromboprophylaxis following TKA.

It is not clear whether these findings could be extrapolated to a Western cohort, in whom chemoprophylaxis is commonly used. There may be ways, by which the risk of DVT can be reduced other than by adjusting the tourniquet strategy or administering chemoprophylaxis. Several authors have reported a reduced risk using mechanical intermittent compression of the lower limbs after THA, TKA and Achilles tendon repair.^[@bibr40-2046-3758.69.BJR-2017-0149.R2],[@bibr41-2046-3758.69.BJR-2017-0149.R2]^

The incidence of symptomatic DVT was low, 0.5% (2 of 400), in this study, consistent with the incidence found in other Asian studies.^[@bibr24-2046-3758.69.BJR-2017-0149.R2],[@bibr32-2046-3758.69.BJR-2017-0149.R2],[@bibr33-2046-3758.69.BJR-2017-0149.R2]^ The two patients in the late release group with a symptomatic DVT both had many thrombi, with thrombus in the left femoral vein and peroneal vein in the first patient, and in the right femoral and popliteal veins in the second. Some authors have suggested that a thrombus in the calf is unlikely to produce symptomatic VTE regardless of the size, and therefore anticoagulation is unnecessary.^[@bibr42-2046-3758.69.BJR-2017-0149.R2],[@bibr43-2046-3758.69.BJR-2017-0149.R2]^ Kakkar et al^[@bibr44-2046-3758.69.BJR-2017-0149.R2]^ and Wang et al^[@bibr45-2046-3758.69.BJR-2017-0149.R2]^ also proposed that thrombi in the calf are attached securely and resolve rapidly and spontaneously. Parisi et al^[@bibr46-2046-3758.69.BJR-2017-0149.R2]^ found that only 2.9% of distal calf DVTs progressed proximally, and Schellong et al^[@bibr47-2046-3758.69.BJR-2017-0149.R2]^ stated that 80% to 90% of distal DVTs do not require anticoagulant treatment. In our study, anticoagulants were not given to patients with a distal DVT. Rivaroxaban was used for patients with a proximal DVT under the guidance of a haematologist. None of the patients developed a recurrent DVT, proximal propagation or a fatal PE. The symptoms in the two patients with a symptomatic DVT resolved following anticoagulant treatment, and the thrombus resolved completely in all patients with a DVT by three months post-operatively.

This study had limitations. First, the surgeons were not blinded to the tourniquet strategy, which may impose some bias. This lack of blinding is hard to avoid. However, the ultrasonographers were blinded to the tourniquet strategy. Secondly, the diagnostic accuracy of ultrasonography is not 100%, although it is widely accepted as an alternative method to venography for the diagnosis of a DVT.^[@bibr48-2046-3758.69.BJR-2017-0149.R2]^ Venography is invasive, involves the injection of contrast and is more expensive than ultrasound.^[@bibr49-2046-3758.69.BJR-2017-0149.R2]-[@bibr51-2046-3758.69.BJR-2017-0149.R2]^ Thirdly, our study was performed in a single institution by a single surgeon. It is possible that our findings may not be generalisable to other patients, other centres or other surgeons. Our patients were all Asian with a mean BMI that was notably lower than that used in many studies involving Western patients. Further multicentre prospective trials are needed to determine whether our findings may be generalisable to other groups. Lastly, we did not routinely treat patients with chemoprophylaxis for DVT, which could have influenced the results. We did not report any clinical outcome data, such as the Oxford Knee Score.^[@bibr52-2046-3758.69.BJR-2017-0149.R2]^ Additionally, there was no long-term follow-up. Some patients may have developed a DVT after the ultrasound examination or after the review three months post-operatively. Although these potential limitations exist, the present study provides evidence that releasing the tourniquet immediately after introducing the components at TKA may reduce the risk of DVT while preserving the advantages of using a tourniquet and without increasing the rate of other complications.
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